NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2018

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Bipolar DisorderDepressive Episode

Interventions

DRUG

Bezafibrate

30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.

Trial Locations (1)

02114

RECRUITING

The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, Boston